{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:35:20Z","timestamp":1793763320883,"version":"4.6.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2020M671162"],"award-info":[{"award-number":["2020M671162"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82141108"],"award-info":[{"award-number":["82141108"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20201350"],"award-info":[{"award-number":["BK20201350"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Osteoporosis has a profound influence on public health. First-line bisphosphonates often cause osteonecrosis of the jaw meanwhile inhibiting osteoclasts. Therefore, it is important to develop effective treatments. The results of this study showed that the increased level of NFATc1 m6A methylation caused by zoledronic acid (ZOL), with 4249A as the functional site, is highly correlated with the decreased bone resorption of osteoclasts. Upstream, METTL14 regulates osteoclast bone absorption through the methylation functional site of NFATc1. Downstream, YTHDF1 and YTHDF2 show antagonistic effects on the post-transcriptional regulation of NFATc1 after the m6A methylation level is elevated by METTL14. In this study, meRIP-Seq, luciferase reporter assays, meRIP and other methods were used to elucidate the NFATc1 regulatory mechanism of osteoclasts from the perspective of RNA methylation. In addition, EphA2 overexpression on exosomes is an effective biological method for targeted delivery of METTL14 into osteoclasts. Importantly, this study shows that METTL14 released by exosomes can increase the m6A methylation level of NFATc1 to inhibit osteoclasts, help postmenopausal osteoporosis patients preserve bone mass, and avoid triggering osteonecrosis of the jaw, thus becoming a new bioactive molecule for the treatment of osteoporosis.<\/jats:p>","DOI":"10.1038\/s41419-023-06263-4","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T13:01:45Z","timestamp":1699880505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Exosome-targeted delivery of METTL14 regulates NFATc1 m6A methylation levels to correct osteoclast-induced bone resorption"],"prefix":"10.1038","volume":"14","author":[{"given":"Jin-Gang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-hui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-jun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-jia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6757-7674","authenticated-orcid":false,"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,13]]},"reference":[{"key":"6263_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1590\/0004-2730000003039","volume":"58","author":"SS Maeda","year":"2014","unstructured":"Maeda SS, Lazaretti-Castro M. An overview on the treatment of postmenopausal osteoporosis. Arq Bras Endocrinol Metab. 2014;58:162\u201371.","journal-title":"Arq Bras Endocrinol Metab"},{"key":"6263_CR2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.fertnstert.2019.10.004","volume":"112","author":"WD Schlaff","year":"2019","unstructured":"Schlaff WD. Introduction: an update on bone metabolism and osteoporosis. Fertil Steril. 2019;112:773\u20134.","journal-title":"Fertil Steril"},{"key":"6263_CR3","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00198-015-3093-2","volume":"26","author":"L Si","year":"2015","unstructured":"Si L, Winzenberg TM, Jiang Q, Chen M, Palmer AJ. Projection of osteoporosis-related fractures and costs in China: 2010-2050. Osteoporos Int. 2015;26:1929\u201337.","journal-title":"Osteoporos Int"},{"key":"6263_CR4","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s40265-021-01625-8","volume":"81","author":"AC van der Burgh","year":"2021","unstructured":"van der Burgh AC, de Keyser CE, Zillikens MC, Stricker BH. The effects of osteoporotic and non-osteoporotic medications on fracture risk and bone mineral density. Drugs. 2021;81:1831\u201358.","journal-title":"Drugs"},{"key":"6263_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41413-021-00143-3","volume":"9","author":"X Zhu","year":"2021","unstructured":"Zhu X, Bai W, Zheng H. Twelve years of GWAS discoveries for osteoporosis and related traits: advances, challenges and applications. Bone Res. 2021;9:23.","journal-title":"Bone Res"},{"key":"6263_CR6","doi-asserted-by":"publisher","first-page":"e0179248","DOI":"10.1371\/journal.pone.0179248","volume":"12","author":"SY Gao","year":"2017","unstructured":"Gao SY, Zheng GS, Wang L, Liang YJ, Zhang SE, Lao XM, et al. Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB. PLoS ONE. 2017;12:e0179248.","journal-title":"PLoS ONE"},{"key":"6263_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","volume":"49","author":"RG Russell","year":"2011","unstructured":"Russell RG. Bisphosphonates: the first 40 years. Bone. 2011;49:2\u201319.","journal-title":"Bone"},{"key":"6263_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2174\/092986708783330638","volume":"15","author":"W Sipos","year":"2008","unstructured":"Sipos W, Pietschmann P, Rauner M. Strategies for novel therapeutic approaches targeting cytokines and signaling pathways of osteoclasto- and osteoblastogenesis in the fight against immune-mediated bone and joint diseases. Curr Med Chem. 2008;15:127\u201336.","journal-title":"Curr Med Chem"},{"key":"6263_CR9","doi-asserted-by":"publisher","first-page":"116184","DOI":"10.1016\/j.bone.2021.116184","volume":"153","author":"JI Aguirre","year":"2021","unstructured":"Aguirre JI, Castillo EJ, Kimmel DB. Preclinical models of medication-related osteonecrosis of the jaw (MRONJ). Bone. 2021;153:116184.","journal-title":"Bone"},{"key":"6263_CR10","doi-asserted-by":"publisher","first-page":"115336","DOI":"10.1016\/j.bone.2020.115336","volume":"136","author":"A Fontalis","year":"2020","unstructured":"Fontalis A, Eastell R. The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis. Bone. 2020;136:115336.","journal-title":"Bone"},{"key":"6263_CR11","doi-asserted-by":"publisher","first-page":"115850","DOI":"10.1016\/j.bone.2021.115850","volume":"145","author":"PR Jensen","year":"2021","unstructured":"Jensen PR, Andersen TL, Chavassieux P, Roux JP, Delaisse JM. Bisphosphonates impair the onset of bone formation at remodeling sites. Bone. 2021;145:115850.","journal-title":"Bone"},{"key":"6263_CR12","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/JPER.18-0644","volume":"90","author":"M Castro","year":"2019","unstructured":"Castro M, Torres P, Solano L, Cordova LA, Torres VA. Histatin-1 counteracts the cytotoxic and antimigratory effects of zoledronic acid in endothelial and osteoblast-like cells. J Periodontol. 2019;90:766\u201374.","journal-title":"J Periodontol"},{"key":"6263_CR13","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1007\/s00784-018-2385-2","volume":"22","author":"JD Kun-Darbois","year":"2018","unstructured":"Kun-Darbois JD, Libouban H, Mabilleau G, Pascaretti-Grizon F, Chappard D. Bone mineralization and vascularization in bisphosphonate-related osteonecrosis of the jaw: an experimental study in the rat. Clin Oral Investig. 2018;22:2997\u20133006.","journal-title":"Clin Oral Investig"},{"key":"6263_CR14","doi-asserted-by":"publisher","first-page":"115117","DOI":"10.1016\/j.bone.2019.115117","volume":"144","author":"SY Gao","year":"2021","unstructured":"Gao SY, Lin RB, Huang SH, Liang YJ, Li X, Zhang SE, et al. PDGF-BB exhibited therapeutic effects on rat model of bisphosphonate-related osteonecrosis of the jaw by enhancing angiogenesis and osteogenesis. Bone. 2021;144:115117.","journal-title":"Bone"},{"key":"6263_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2353\/ajpath.2010.090592","volume":"177","author":"Y Bi","year":"2010","unstructured":"Bi Y, Gao Y, Ehirchiou D, Cao C, Kikuiri T, Le A, et al. Bisphosphonates cause osteonecrosis of the jaw-like disease in mice. Am J Pathol. 2010;177:280\u201390.","journal-title":"Am J Pathol"},{"key":"6263_CR16","doi-asserted-by":"publisher","first-page":"452737","DOI":"10.1155\/2014\/452737","volume":"2014","author":"AM Hinson","year":"2014","unstructured":"Hinson AM, Smith CW, Siegel ER, Stack BC Jr. Is bisphosphonate-related osteonecrosis of the jaw an infection? A histological and microbiological ten-year summary. Int J Dent. 2014;2014:452737.","journal-title":"Int J Dent"},{"key":"6263_CR17","doi-asserted-by":"publisher","first-page":"471035","DOI":"10.1155\/2014\/471035","volume":"2014","author":"L Rasmusson","year":"2014","unstructured":"Rasmusson L, Abtahi J. Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatment. Int J Dent. 2014;2014:471035.","journal-title":"Int J Dent"},{"key":"6263_CR18","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/j.1601-0825.2012.01916.x","volume":"18","author":"X Wei","year":"2012","unstructured":"Wei X, Pushalkar S, Estilo C, Wong C, Farooki A, Fornier M, et al. Molecular profiling of oral microbiota in jawbone samples of bisphosphonate-related osteonecrosis of the jaw. Oral Dis. 2012;18:602\u201312.","journal-title":"Oral Dis"},{"key":"6263_CR19","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.ijom.2013.06.011","volume":"42","author":"H Tsurushima","year":"2013","unstructured":"Tsurushima H, Kokuryo S, Sakaguchi O, Tanaka J, Tominaga K. Bacterial promotion of bisphosphonate-induced osteonecrosis in Wistar rats. Int J Oral Maxillofac Surg. 2013;42:1481\u20137.","journal-title":"Int J Oral Maxillofac Surg"},{"key":"6263_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.gpb.2017.03.002","volume":"15","author":"PJ Batista","year":"2017","unstructured":"Batista PJ. The RNA modification N(6)-methyladenosine and its implications in human disease. Genomics Proteom Bioinform. 2017;15:154\u201363.","journal-title":"Genomics Proteom Bioinform"},{"key":"6263_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41392-020-00450-x","volume":"6","author":"X Jiang","year":"2021","unstructured":"Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin Z, et al. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021;6:74.","journal-title":"Signal Transduct Target Ther"},{"key":"6263_CR22","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.molcel.2016.05.041","volume":"63","author":"P Wang","year":"2016","unstructured":"Wang P, Doxtader KA, Nam Y. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. Mol Cell. 2016;63:306\u201317.","journal-title":"Mol Cell"},{"key":"6263_CR23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/nature24678","volume":"552","author":"I Barbieri","year":"2017","unstructured":"Barbieri I, Tzelepis K, Pandolfini L, Shi J, Millan-Zambrano G, Robson SC, et al. Promoter-bound METTL3 maintains myeloid leukaemia by m(6)A-dependent translation control. Nature. 2017;552:126\u201331.","journal-title":"Nature"},{"key":"6263_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.stem.2017.11.016","volume":"22","author":"H Weng","year":"2018","unstructured":"Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, et al. METTL14 inhibits hematopoietic stem\/progenitor differentiation and promotes leukemogenesis via mRNA m(6)A modification. Cell Stem Cell. 2018;22:191\u2013205.e199.","journal-title":"Cell Stem Cell"},{"key":"6263_CR25","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/nchembio.687","volume":"7","author":"G Jia","year":"2011","unstructured":"Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7:885\u20137.","journal-title":"Nat Chem Biol"},{"key":"6263_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.molcel.2012.10.015","volume":"49","author":"G Zheng","year":"2013","unstructured":"Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM, Li CJ, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 2013;49:18\u201329.","journal-title":"Mol Cell"},{"key":"6263_CR27","doi-asserted-by":"crossref","unstructured":"Roundtree IA, Luo GZ, Zhang Z, Wang X, Zhou T, Cui Y, et al. YTHDC1 mediates nuclear export of N(6)-methyladenosine methylated mRNAs. Elife 2017;6:e31311.","DOI":"10.7554\/eLife.31311"},{"key":"6263_CR28","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1101\/gad.340695.120","volume":"34","author":"L Lasman","year":"2020","unstructured":"Lasman L, Krupalnik V, Viukov S, Mor N, Aguilera-Castrejon A, Schneir D, et al. Context-dependent functional compensation between Ythdf m(6)A reader proteins. Genes Dev. 2020;34:1373\u201391.","journal-title":"Genes Dev"},{"key":"6263_CR29","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.cell.2015.08.011","volume":"162","author":"CR Alarcon","year":"2015","unstructured":"Alarcon CR, Goodarzi H, Lee H, Liu X, Tavazoie S, Tavazoie SF. HNRNPA2B1 is a mediator of m(6)A-dependent nuclear RNA processing events. Cell. 2015;162:1299\u2013308.","journal-title":"Cell"},{"key":"6263_CR30","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1093\/nar\/gkx141","volume":"45","author":"N Liu","year":"2017","unstructured":"Liu N, Zhou KI, Parisien M, Dai Q, Diatchenko L, Pan T. N6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein. Nucleic Acids Res. 2017;45:6051\u201363.","journal-title":"Nucleic Acids Res"},{"key":"6263_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.gpb.2018.04.002","volume":"16","author":"S Liao","year":"2018","unstructured":"Liao S, Sun H, Xu C. YTH domain: a family of N(6)-methyladenosine (m(6)A) readers. Genomics Proteom Bioinform. 2018;16:99\u2013107.","journal-title":"Genomics Proteom Bioinform"},{"key":"6263_CR32","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.cell.2017.05.045","volume":"169","author":"IA Roundtree","year":"2017","unstructured":"Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA modifications in gene expression regulation. Cell. 2017;169:1187\u20131200.","journal-title":"Cell"},{"key":"6263_CR33","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.stem.2014.09.019","volume":"15","author":"PJ Batista","year":"2014","unstructured":"Batista PJ, Molinie B, Wang J, Qu K, Zhang J, Li L, et al. m(6)A RNA modification controls cell fate transition in mammalian embryonic stem cells. Cell Stem Cell. 2014;15:707\u201319.","journal-title":"Cell Stem Cell"},{"key":"6263_CR34","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/nm.4416","volume":"23","author":"LP Vu","year":"2017","unstructured":"Vu LP, Pickering BF, Cheng Y, Zaccara S, Nguyen D, Minuesa G, et al. The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med. 2017;23:1369\u201376.","journal-title":"Nat Med"},{"key":"6263_CR35","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-018-0538-8","volume":"561","author":"J Choe","year":"2018","unstructured":"Choe J, Lin S, Zhang W, Liu Q, Wang L, Ramirez-Moya J, et al. mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature. 2018;561:556\u201360.","journal-title":"Nature"},{"key":"6263_CR36","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/hep.28885","volume":"65","author":"JZ Ma","year":"2017","unstructured":"Ma JZ, Yang F, Zhou CC, Liu F, Yuan JH, Wang F, et al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N(6) -methyladenosine-dependent primary MicroRNA processing. Hepatology. 2017;65:529\u201343.","journal-title":"Hepatology"},{"key":"6263_CR37","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nature21355","volume":"542","author":"BS Zhao","year":"2017","unstructured":"Zhao BS, Wang X, Beadell AV, Lu Z, Shi H, Kuuspalu A, et al. m(6)A-dependent maternal mRNA clearance facilitates zebrafish maternal-to-zygotic transition. Nature. 2017;542:475\u20138.","journal-title":"Nature"},{"key":"6263_CR38","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1002\/ajmg.a.31368","volume":"140","author":"MM Cohen Jr","year":"2006","unstructured":"Cohen MM Jr. The new bone biology: pathologic, molecular, and clinical correlates. Am J Med Genet A. 2006;140:2646\u2013706.","journal-title":"Am J Med Genet A"},{"key":"6263_CR39","doi-asserted-by":"publisher","first-page":"25103","DOI":"10.1074\/jbc.R109.041087","volume":"285","author":"LJ Raggatt","year":"2010","unstructured":"Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. J Biol Chem. 2010;285:25103\u20138.","journal-title":"J Biol Chem"},{"key":"6263_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03915-1","volume":"12","author":"W Wang","year":"2021","unstructured":"Wang W, Qiao SC, Wu XB, Sun B, Yang JG, Li X, et al. Circ_0008542 in osteoblast exosomes promotes osteoclast-induced bone resorption through m6A methylation. Cell Death Dis. 2021;12:628.","journal-title":"Cell Death Dis"},{"key":"6263_CR41","doi-asserted-by":"publisher","first-page":"115153","DOI":"10.1016\/j.bone.2019.115153","volume":"131","author":"HM Kim","year":"2020","unstructured":"Kim HM, He L, Lee S, Park C, Kim DH, Han HJ, et al. Inhibition of osteoclasts differentiation by CDC2-induced NFATc1 phosphorylation. Bone. 2020;131:115153.","journal-title":"Bone"},{"key":"6263_CR42","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00018-012-1238-4","volume":"70","author":"T Oikawa","year":"2013","unstructured":"Oikawa T, Kuroda Y, Matsuo K. Regulation of osteoclasts by membrane-derived lipid mediators. Cell Mol Life Sci. 2013;70:3341\u201353.","journal-title":"Cell Mol Life Sci"},{"key":"6263_CR43","doi-asserted-by":"crossref","unstructured":"Kang JY, Kang N, Yang YM, Hong JH, Shin DM. The role of Ca(2+)-NFATc1 signaling and its modulation on osteoclastogenesis. Int J Mol Sci. 2020;21:3646.","DOI":"10.3390\/ijms21103646"},{"key":"6263_CR44","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/jbmr.1885","volume":"28","author":"BF Boyce","year":"2013","unstructured":"Boyce BF. Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res. 2013;28:711\u201322.","journal-title":"J Bone Miner Res"},{"key":"6263_CR45","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1600-065X.2009.00821.x","volume":"231","author":"T Negishi-Koga","year":"2009","unstructured":"Negishi-Koga T, Takayanagi H. Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol Rev. 2009;231:241\u201356.","journal-title":"Immunol Rev"},{"key":"6263_CR46","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S1534-5807(02)00369-6","volume":"3","author":"H Takayanagi","year":"2002","unstructured":"Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3:889\u2013901.","journal-title":"Dev Cell"},{"key":"6263_CR47","doi-asserted-by":"publisher","first-page":"233","DOI":"10.11005\/jbm.2014.21.4.233","volume":"21","author":"JH Kim","year":"2014","unstructured":"Kim JH, Kim N. Regulation of NFATc1 in osteoclast differentiation. J Bone Metab. 2014;21:233\u201341.","journal-title":"J Bone Metab"},{"key":"6263_CR48","doi-asserted-by":"publisher","first-page":"35209","DOI":"10.1074\/jbc.M505815200","volume":"280","author":"K Kim","year":"2005","unstructured":"Kim K, Kim JH, Lee J, Jin HM, Lee SH, Fisher DE, et al. Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem. 2005;280:35209\u201316.","journal-title":"J Biol Chem"},{"key":"6263_CR49","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809\u201322.","journal-title":"N Engl J Med"},{"key":"6263_CR50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s10020-021-00276-5","volume":"27","author":"W Lin","year":"2021","unstructured":"Lin W, Li XF, Ren DC, Song M, Duan L, Liu JZ, et al. Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression. Mol Med. 2021;27:19.","journal-title":"Mol Med"},{"key":"6263_CR51","doi-asserted-by":"publisher","first-page":"107611","DOI":"10.1016\/j.pharmthera.2020.107611","volume":"214","author":"KH Lu","year":"2020","unstructured":"Lu KH, Lu EW, Lin CW, Yang JS, Yang SF. New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma. Pharmacol Ther. 2020;214:107611.","journal-title":"Pharmacol Ther"},{"key":"6263_CR52","doi-asserted-by":"publisher","first-page":"115493","DOI":"10.1016\/j.bone.2020.115493","volume":"139","author":"MJ Rogers","year":"2020","unstructured":"Rogers MJ, Monkkonen J, Munoz MA. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone. 2020;139:115493.","journal-title":"Bone"},{"key":"6263_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07568-9","volume":"20","author":"L Wang","year":"2020","unstructured":"Wang L, Fang D, Xu J, Luo R. Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review. BMC Cancer. 2020;20:1059.","journal-title":"BMC Cancer"},{"key":"6263_CR54","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nature14234","volume":"518","author":"N Liu","year":"2015","unstructured":"Liu N, Dai Q, Zheng G, He C, Parisien M, Pan T. N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature. 2015;518:560\u20134.","journal-title":"Nature"},{"key":"6263_CR55","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1093\/nar\/gky130","volume":"46","author":"D Yang","year":"2018","unstructured":"Yang D, Qiao J, Wang G, Lan Y, Li G, Guo X, et al. N6-Methyladenosine modification of lincRNA 1281 is critically required for mESC differentiation potential. Nucleic Acids Res. 2018;46:3906\u201320.","journal-title":"Nucleic Acids Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06263-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06263-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06263-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T13:02:15Z","timestamp":1699880535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06263-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":55,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["6263"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-06263-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,13]]},"assertion":[{"value":"8 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All clinical specimens in this study were approved by the Ethics Committee of the School of Stomatology of Nanjing Medical University. Written informed consent was received from all patients. All animal experiments in this study were conducted according to the Guidelines for Animal Experimentation of the School of Stomatology of Nanjing Medical University. The Laboratory Animal Care and Use Committees of the hospital approved all experimental procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"738"}}